• 1
    The European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 813.
  • 2
    Harris A. Current regimens for treatment of Helicobacter pylori infection. Br Med Bull 1998; 54: 195205.
  • 3
    Penston JG & McColl KEL. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997; 43: 22343.
  • 4
    Gasbarrini A, Ojetti V & Armuzzi A, et al. Efficacy of a multistep strategy for Helicobacter pylori eradica tion. Aliment Pharmacol Ther 2000; 14: 7983.DOI: 10.1046/j.1365-2036.2000.00685.x
  • 5
    Cammarota G, Cannizzaro O & Ojetti V, et al. Five-days regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxicillin or tinidazole for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 737.DOI: 10.1046/j.1365-2036.2000.00664.x
  • 6
    Deltenre M, Ntounda R & Jonas C, et al. Eradication of Helicobacter pylori: why does it fail? Ital J Gastroenterol Hepatol 1998; 30(Suppl. 3): S3268.
  • 7
    Nord CE, Heimdal A & Kager L, et al. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis 1986; 49: 6472.
  • 8
    Adamsson I, Nord CE & Lundquist P, et al. Comparative effects of omeprazole, amoxycillin, plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. J Antimicrob Chemother 1999; 44: 62940.DOI: 10.1093/jac/44.5.629
  • 9
    Donaldson RmJr & Toskes PP. The relationship of enteric bacteric population to gastrointestinal function and disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease. New York: WB Saunders, 1989: 107–13.
  • 10
    Conway PL, Gorbach SL & Goldin BR, et al. Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Diary Sci 1987; 70: 112.
  • 11
    Lewis SJ & Freedman AR. Rewiev article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998; 12: 80722.DOI: 10.1046/j.1365-2036.1998.00386.x
  • 12
    Jack RW, Tagg JR & Ray B. Bacteriocines of gram-positive bacteria. Microbiol Rev 1995; 59: 171200.
  • 13
    Chauviere G, Coconnier MH & Karneis S, et al. Competitive exclusion of diarrheagenic Escherichia coli (ETEC) from human enterocyte-like Caco-2 cells by heat killed Lactobacillus. FEMS Microbiol Lett 1992; 91: 2138.
  • 14
    Moyen EN, Bonneville F & Fauchere JL. Effect of erithromycin and an extract of heat-killed Lactobacillus acidophilus on intestinal colonization and traslocation of Campylobacter jejuni in the axenic mouse. Ann Inst Pasteur/Microbiol 1986; 137A: 199207.
  • 15
    Kabir AMA, Aiba Y & Takagi A, et al. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 1997; 41: 4955.
  • 16
    Coconnier MH, Lievin V & Hemery E, et al. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus Strain LB. Appl Env Microbiol 1998; 64: 457380.
  • 17
    Michetti P, Dorta G & Wiesel PH, et al. Effect of Whey-based Culture Supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 1999; 60: 2039.
  • 18
    Boulloche J, Mouterde O & Mallet E, et al. Management of acute diarrhoea in infants and young children: controlled study of the antidiarrhoeal efficacy of killed L. acidophilus (LB Strain) versus a placebo and a reference drug (loperamide). Ann Pediatr 1994; 41: 45763.
  • 19
    Halpern GM, Prindiville T & Blankenburg M, et al. Treatment of Irritable Bowel Syndrome with Lacteol Fort: a randomized double-blind, cross-over trial. Am J Gastroenterol 1996; 81: 157985.
  • 20
    Goddard AF & Logan RP. Review article: urea breath tests for detecting Helicobacter pylori. Aliment Pharmacol Ther 1997; 11: 6419.
  • 21
    De Boer WA, Thys JC & Borody TJ, et al. Proposal for use of a standard side effect scoring system in studies exploring treatment regimens. Eur J Gastroenterol Hepatol 1996; 8: 6413.
  • 22
    Marteau P & Rambaud JC. Potential of using lactic acid bacteria for therapy and immunomodulation in man. FEMS Microbiol Rev 1993; 12: 20720.
  • 23
    Perdigon G, Medici M & Bibas Bonet de Jorrat ME, et al. Immunomodulating effects of lactic acid bacteria on mucosal and tumoral immunity. Int J Immunotherapy; IX (1993; 1): 2952.
  • 24
    Fourniat J, Colomban C & Linxe C, et al. Heat-killed Lactobacillus acidophilus inhibits adhesion of Escherichia coli B41 to Hela cells. Ann Rech Vet 1992; 23: 36170.
  • 25
    Bodilis JY. Controlled clinical trial of Lacteol Fort compared with a placebo and reference drug in the treatment of acute diarrhea in the adult. Med Actuelle 1983; 10: 2325.